Long-Term Hepatitis B Virus (HBV) Response to Lamivudine-Containing Highly Active Antiretroviral Therapy in HIV-HBV Co-Infected Patients in Thailand

@inproceedings{Khamduang2012LongTermHB,
  title={Long-Term Hepatitis B Virus (HBV) Response to Lamivudine-Containing Highly Active Antiretroviral Therapy in HIV-HBV Co-Infected Patients in Thailand},
  author={Woottichai Khamduang and Catherine Gaudy-Graffin and Nicole Ngo-Giang-Huong and Gonzague Jourdain and Alain Moreau and Nuananong Luekamlung and Guttiga Halue and Yuwadee Buranawanitchakorn and Sura Kunkongkapan and Sudanee Buranabanjasatean and Marc J Lallemant and Wasna Sirirungsi and Alain Goudeau},
  booktitle={PloS one},
  year={2012}
}
BACKGROUND Approximately 4 million of people are co-infected with HIV and Hepatitis B virus (HBV). In resource-limited settings, the majority of HIV-infected patients initiate first-line highly active antiretroviral therapy containing lamivudine (3TC-containing-HAART) and long-term virological response of HBV to lamivudine-containing HAART in co-infected patients is not well known. METHODOLOGY/PRINCIPAL FINDING HIV-HBV co-infected patients enrolled in the PHPT cohort (ClinicalTrials.gov… CONTINUE READING